China National Accord Medicines Corp Ltd Cash Flow Quality Index
China National Accord Medicines Corp Ltd cash flow quality index. China National Accord Medicines Corp Ltd (200028) has a Cash Flow Quality Index of -1.46x as of September 2025. Operating cash flow of HK$-424.00 Million is below net income of HK$291.12 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of China National Accord Medicines Corp Ltd to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of China National Accord Medicines Corp Ltd (1998–2025)
Cash flow quality index of China National Accord Medicines Corp Ltd from 1998 to 2025. Historical Cash Flow Quality Index for China National Accord Medicines Corp Ltd across 27 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore debt repayment capacity of China National Accord Medicines Corp Ltd to assess how comfortably operating cash covers total debt obligations.
China National Accord Medicines Corp Ltd Cash Flow Quality Index by Year (1998–2025)
China National Accord Medicines Corp Ltd cash flow quality index by year from 1998 to 2025. Year-by-year earnings quality comparison for China National Accord Medicines Corp Ltd. For the full cash flow conversion analysis, see cash flow conversion of China National Accord Medicines Corp Ltd.
| Year | Quality Index | Operating CF (HKD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.44x | HK$1.64 Billion | HK$1.14 Billion | ▼ -89.5% |
| 2024 | 13.80x | HK$3.27 Billion | HK$237.00 Million | ▲ +820.4% |
| 2023 | 1.50x | HK$2.94 Billion | HK$1.96 Billion | ▲ +3.8% |
| 2022 | 1.45x | HK$2.56 Billion | HK$1.77 Billion | ▲ +33.4% |
| 2021 | 1.08x | HK$1.66 Billion | HK$1.53 Billion | ▲ +24.1% |
| 2020 | 0.87x | HK$1.50 Billion | HK$1.72 Billion | ▼ -35.2% |
| 2019 | 1.35x | HK$2.00 Billion | HK$1.48 Billion | ▲ +37.4% |
| 2018 | 0.98x | HK$1.32 Billion | HK$1.35 Billion | ▼ -11.7% |
| 2017 | 1.11x | HK$1.29 Billion | HK$1.16 Billion | ▼ -3.3% |
| 2016 | 1.15x | HK$1.47 Billion | HK$1.28 Billion | ▼ -13.7% |
| 2015 | 1.33x | HK$1.05 Billion | HK$787.35 Million | ▲ +211.9% |
| 2014 | -1.19x | HK$-796.70 Million | HK$669.84 Million | ▼ -236.6% |
| 2013 | 0.87x | HK$465.03 Million | HK$534.22 Million | ▲ +30.0% |
| 2012 | 0.67x | HK$323.96 Million | HK$483.68 Million | ▼ -3.4% |
| 2011 | 0.69x | HK$227.32 Million | HK$327.82 Million | ▼ -57.2% |
| 2010 | 1.62x | HK$428.16 Million | HK$264.22 Million | ▲ +18.6% |
| 2009 | 1.37x | HK$270.85 Million | HK$198.26 Million | ▼ -10.0% |
| 2008 | 1.52x | HK$246.58 Million | HK$162.45 Million | ▲ +116.2% |
| 2007 | 0.70x | HK$87.70 Million | HK$124.91 Million | ▼ -70.0% |
| 2006 | 2.34x | HK$181.73 Million | HK$77.76 Million | ▼ -43.6% |
| 2005 | 4.15x | HK$148.28 Million | HK$35.77 Million | ▼ -15.4% |
| 2004 | 4.90x | HK$130.30 Million | HK$26.58 Million | ▼ -8.9% |
| 2003 | 5.38x | HK$81.22 Million | HK$15.11 Million | ▼ -20.1% |
| 2002 | 6.73x | HK$28.76 Million | HK$4.28 Million | ▲ +227.3% |
| 2001 | 2.06x | HK$71.16 Million | HK$34.61 Million | ▲ +130.7% |
| 1999 | 0.89x | HK$22.84 Million | HK$25.62 Million | ▲ +141.6% |
| 1998 | 0.37x | HK$5.21 Million | HK$14.12 Million | — |